
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: Light Chain Bioscience A brand of Novimmune SA. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven...
Next-generation antibody drug discovery,immunology,bispecific antibody drugs,and clinical development
Light chain bioscience | novimmune sa operates in the Biotechnology research industry.
Light chain bioscience | novimmune sa's revenue is 11m - 100m
Light chain bioscience | novimmune sa has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.